Skip to main content
. Author manuscript; available in PMC: 2017 May 7.
Published in final edited form as: J Cyst Fibros. 2017 Jan 20;16(3):318–326. doi: 10.1016/j.jcf.2017.01.002

Table 2.

Heterogeneity in the reporting of FEV1 endpoints in pivotal clinical trials for select chronic CF therapies.

Change in FEV1 FEV1 Units
Liters % Predicted
Relative Change rhDNase(50), Hypertonic saline(62), Aztreonam(52) Inhaled tobramycin(51), Azithromycin(63) (64), Aztreonam(52), Ivacaftor(54), Tobramycin inhalation powder ((65)), Mannitol ((66)), Ataluren ((67)) Lumacaftor-Ivacaftor(55)
Absolute Change Azithromycin(63) (64), Hypertonic saline(62), Mannitol(66) Azithromycin (64), Ivacaftor (54), Ivacaftor-Lumacaftor(55)